Is SVRA or FATE more profitable?

Savara has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Fate Therapeutics -2,056.79% -58.89% -39.39%

Does the media refer more to SVRA or FATE?

In the previous week, Fate Therapeutics had 1 more articles in the media than Savara. MarketBeat recorded 4 mentions for Fate Therapeutics and 3 mentions for Savara. Savara's average media sentiment score of 0.84 beat Fate Therapeutics' score of 0.39 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRVS or FATE?

In the previous week, Corvus Pharmaceuticals had 5 more articles in the media than Fate Therapeutics. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.39 beat Corvus Pharmaceuticals' score of -0.17 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, FATE or MGTX?

MeiraGTx has higher revenue and earnings than Fate Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fate Therapeutics $6.65M 48.64 -$136.32M -$1.09 N/A MeiraGTx $81.39M 14.89 -$114.20M -$1.48 N/A

Does the media favor FATE or MGTX?

In the previous week, Fate Therapeutics had 2 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for MeiraGTx. Fate Therapeutics' average media sentiment score of 0.39 beat MeiraGTx's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor WVE or FATE?

In the previous week, WAVE Life Sciences had 16 more articles in the media than Fate Therapeutics. MarketBeat recorded 20 mentions for WAVE Life Sciences and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.39 beat WAVE Life Sciences' score of -0.06 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FBRX or FATE?

In the previous week, Forte Biosciences had 2 more articles in the media than Fate Therapeutics. MarketBeat recorded 6 mentions for Forte Biosciences and 4 mentions for Fate Therapeutics. Forte Biosciences' average media sentiment score of 0.64 beat Fate Therapeutics' score of 0.39 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fate Therapeutics (FATE) Competitors

$2.78 -0.03 (-0.89%)

As of 12:28 PM Eastern

Compare

FATE vs. SVRA, CRVS, MGTX, WVE, and FBRX

Should you buy Fate Therapeutics stock or one of its competitors? MarketBeat compares Fate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fate Therapeutics include Savara (SVRA), Corvus Pharmaceuticals (CRVS), MeiraGTx (MGTX), WAVE Life Sciences (WVE), and Forte Biosciences (FBRX). These companies are all part of the "biotechnology" industry.

How does Fate Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

87.9% of Savara shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Savara has higher earnings, but lower revenue than Fate Therapeutics. Savara is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Fate Therapeutics	$6.65M	48.64	-$136.32M	-$1.09	N/A

In the previous week, Fate Therapeutics had 1 more articles in the media than Savara. MarketBeat recorded 4 mentions for Fate Therapeutics and 3 mentions for Savara. Savara's average media sentiment score of 0.84 beat Fate Therapeutics' score of 0.39 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Savara has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

Savara currently has a consensus price target of $10.14, suggesting a potential upside of 75.94%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 84.68%. Given Fate Therapeutics' higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Savara has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Summary

Savara and Fate Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Corvus Pharmaceuticals presently has a consensus price target of $33.33, suggesting a potential upside of 146.28%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 84.68%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Corvus Pharmaceuticals is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Corvus Pharmaceuticals' return on equity of -36.15% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Corvus Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market.

In the previous week, Corvus Pharmaceuticals had 5 more articles in the media than Fate Therapeutics. MarketBeat recorded 9 mentions for Corvus Pharmaceuticals and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.39 beat Corvus Pharmaceuticals' score of -0.17 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals has higher earnings, but lower revenue than Fate Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A
Fate Therapeutics	$6.65M	48.64	-$136.32M	-$1.09	N/A

Summary

Corvus Pharmaceuticals beats Fate Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to MeiraGTx?

Fate Therapeutics (NASDAQ:FATE) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

MeiraGTx has a net margin of -151.12% compared to Fate Therapeutics' net margin of -2,056.79%. MeiraGTx's return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
MeiraGTx	-151.12%	N/A	-54.96%

Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Fate Therapeutics had 2 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for MeiraGTx. Fate Therapeutics' average media sentiment score of 0.39 beat MeiraGTx's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has higher revenue and earnings than Fate Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	48.64	-$136.32M	-$1.09	N/A
MeiraGTx	$81.39M	14.89	-$114.20M	-$1.48	N/A

Fate Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 84.68%. MeiraGTx has a consensus price target of $26.00, indicating a potential upside of 98.70%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

MeiraGTx beats Fate Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Fate Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

WAVE Life Sciences has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

In the previous week, WAVE Life Sciences had 16 more articles in the media than Fate Therapeutics. MarketBeat recorded 20 mentions for WAVE Life Sciences and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.39 beat WAVE Life Sciences' score of -0.06 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

WAVE Life Sciences presently has a consensus price target of $22.53, indicating a potential upside of 272.69%. Fate Therapeutics has a consensus price target of $5.13, indicating a potential upside of 84.68%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe WAVE Life Sciences is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

WAVE Life Sciences has a net margin of -309.73% compared to Fate Therapeutics' net margin of -2,056.79%. WAVE Life Sciences' return on equity of -50.36% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Fate Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	27.88	-$204.38M	-$1.09	N/A
Fate Therapeutics	$6.65M	48.64	-$136.32M	-$1.09	N/A

Summary

WAVE Life Sciences beats Fate Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

In the previous week, Forte Biosciences had 2 more articles in the media than Fate Therapeutics. MarketBeat recorded 6 mentions for Forte Biosciences and 4 mentions for Fate Therapeutics. Forte Biosciences' average media sentiment score of 0.64 beat Fate Therapeutics' score of 0.39 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Forte Biosciences has a beta of 2.6, meaning that its stock price is 160% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Forte Biosciences currently has a consensus price target of $72.50, indicating a potential downside of 5.62%. Fate Therapeutics has a consensus price target of $5.13, indicating a potential upside of 84.68%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Forte Biosciences has higher earnings, but lower revenue than Fate Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Fate Therapeutics	$6.65M	48.64	-$136.32M	-$1.09	N/A

Forte Biosciences has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Summary

Fate Therapeutics beats Forte Biosciences on 10 of the 15 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FATE vs. The Competition

Export

Metric	Fate Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$323.45M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-2.55	9.06	269.93	24.86
Price / Sales	48.64	1,267.27	650.62	108.28
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	1.54	17.63	11.25	6.44
Net Income	-$136.32M	-$13.25M	$3.45B	$347.39M
7 Day Performance	11.00%	5.49%	3.67%	2.69%
1 Month Performance	-10.48%	-1.66%	-0.49%	-0.90%
1 Year Performance	201.17%	61.27%	77.44%	23.51%

Fate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FATE Fate Therapeutics	3.3395 of 5 stars	$2.78 -0.9%	$5.13 +84.7%	+203.9%	$323.22M	$6.65M	N/A	550	News Coverage Upcoming Earnings
SVRA Savara	2.1847 of 5 stars	$5.33 -2.4%	$10.14 +90.3%	+120.8%	$1.12B	N/A	N/A	20	Positive News Upcoming Earnings
CRVS Corvus Pharmaceuticals	2.9005 of 5 stars	$13.37 +0.8%	$33.33 +149.3%	+223.0%	$1.12B	N/A	N/A	30	News Coverage Positive News Earnings Report
MGTX MeiraGTx	3.172 of 5 stars	$11.88 +0.8%	$26.00 +118.9%	+65.9%	$1.09B	$81.39M	N/A	300	Upcoming Earnings Gap Up
WVE WAVE Life Sciences	3.0982 of 5 stars	$5.74 +4.2%	$22.76 +296.6%	-24.6%	$1.09B	$42.73M	N/A	240	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FATE) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fate Therapeutics (FATE) Competitors

FATE vs. SVRA, CRVS, MGTX, WVE, and FBRX

How does Fate Therapeutics compare to Savara?

Summary

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Summary

How does Fate Therapeutics compare to MeiraGTx?

Summary

How does Fate Therapeutics compare to WAVE Life Sciences?

Summary

How does Fate Therapeutics compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fate Therapeutics (FATE) Competitors

FATE vs. SVRA, CRVS, MGTX, WVE, and FBRX

How does Fate Therapeutics compare to Savara?

Do institutionals and insiders have more ownership in SVRA or FATE?

Which has higher valuation and earnings, SVRA or FATE?

Does the media refer more to SVRA or FATE?

Which has more volatility & risk, SVRA or FATE?

Do analysts prefer SVRA or FATE?

Is SVRA or FATE more profitable?

Summary

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Do analysts recommend CRVS or FATE?

Do institutionals and insiders have more ownership in CRVS or FATE?

Is CRVS or FATE more profitable?

Which has more risk and volatility, CRVS or FATE?

Does the media refer more to CRVS or FATE?

Which has stronger valuation and earnings, CRVS or FATE?

Summary

How does Fate Therapeutics compare to MeiraGTx?

Is FATE or MGTX more profitable?

Which has more volatility and risk, FATE or MGTX?

Do institutionals and insiders have more ownership in FATE or MGTX?

Does the media favor FATE or MGTX?

Which has stronger earnings and valuation, FATE or MGTX?

Do analysts rate FATE or MGTX?

Summary

How does Fate Therapeutics compare to WAVE Life Sciences?

Which has more volatility and risk, WVE or FATE?

Does the media favor WVE or FATE?

Do analysts prefer WVE or FATE?

Is WVE or FATE more profitable?

Do institutionals & insiders have more ownership in WVE or FATE?

Which has stronger earnings & valuation, WVE or FATE?

Summary

How does Fate Therapeutics compare to Forte Biosciences?

Does the media favor FBRX or FATE?

Which has more volatility & risk, FBRX or FATE?

Do insiders & institutionals have more ownership in FBRX or FATE?

Do analysts recommend FBRX or FATE?

Which has preferable valuation & earnings, FBRX or FATE?

Is FBRX or FATE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools